Novartis skin-cancer drug meets main goal in Phase II trial

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS) Sonidegib treatment met its primary goal of achieving a "clinically significant tumor response" in a Phase II trial of patients with Basal cell carcinoma, the most common form of skin cancer.

In some patients, tumors disappeared completely within six months of treatment and in others they shrank significantly.

Novartis intends to present the full results of the study at a future scientific meeting.

Meanwhile, Japanese prosecutors have raided Novartis' Tokyo office as part of a criminal probe into whether the company violated regulations by exaggerating the effectiveness of its Diovan hypertension drug in marketing materials.

Officers took documents that they want to look at as part of the investigation.

The alleged breach could lead to fines of up to ¥2M ($19,500) and jail terms of two years.